Matthew Webster on LinkedIn: Formulary Coverage of Brand-Name Adalimumab and Biosimilars (2024)

Great insight as always from William Sarraille . Bill, my thoughts are not only your insight, “cost sharing”, but actually the staff having the knowledge of patent access services, in the clinical setting. I hope you are having a great weekend!Marina Allen Melanie M, MBA

2

4 Comments

We are so sorry for you, and your family’s loss Derek. What a beautiful soul you have, and tribute for your lovely wife.She will be an angel looking over all of you. You, and your family are in my thoughts and prayers… Deepest condolences- Matt

12

1 Comment

BIOSIMILAR UPDATE:“New guidance published by the US FDA suggests that switching studies will no longer be expected as standard to support determinations of biosimilar interchangeability, with the agency instead suggesting that analytical and clinical data will suffice.”Our team at RxAccess Partners LLC provides a full spectrum of payor to patient services for our Biosimilar clients. RX Access Partners brings over a century of combined experience in assisting clients with market access and patient support strategies, from conception to creative execution, including ongoing management and oversight.We look forward in working with you!https://lnkd.in/geGgFjK8

2

Great Insight from Dr. Quinn!

“Since publication of the Interchangeability Guidance, experience has shown that for the products approved as biosimilars to date, the risk in terms of safety or diminished efficacy is insignificant following single or multiple switches between a reference product and a biosimilar product. Accordingly, FDA’s scientific approach to when a switching study or studies may be needed to support a demonstration of interchangeability has evolved,” the FDA wrote in the update.https://lnkd.in/gAz4uCD6

In Beckers Hospital Review physicians stated “Patient Access” was the “BIGGEST BARRIER” to treating new patients. Lets us help you overcome those challenges here RxAccess Partners LLC As we have launched our new website, and have over century of experience within the Market Access Space, we put the patients needs at the forefront, while building solutions to these challenges. We bring complex market access and patient support programs to life through simple concepts and creative execution.We look forward in showcasing our dynamic team and capabilities. “Physicians also reported barriers in prescribing medication as a hindrance to providing care, with 85% of respondents saying lack of patient access was the biggest barrier to treating patients with new therapies. Drug shortages were also a critical barrier in prescribing medication, according to 60% of physicians. “Melanie M, MBA Marina Allen AMCP PCMA #marketaccess#trade#patientaccessservices#productlaunch#reimbursem*nt#specialtypharmacy#managedcare

1

LDT Questions due by June 28th, and live webinar on July 16th.#LDT#FDA